2. Academic Validation
  3. Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro

Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro

  • J Med Chem. 1996 Apr 26;39(9):1757-9. doi: 10.1021/jm950836q.
T S Lin 1,  M Z Luo,  M C Liu,  Y L Zhu,  E Gullen,  G E Dutschman,  Y C Cheng
Affiliations

Affiliation

  • 1 Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520-8066, USA.
PMID: 8627596 DOI: 10.1021/jm950836q
Figures
Products